[
Albergaria, A., Paredes, J., Sousa, B., Milanezi, F., Carneiro, V., Bastos, J., Costa, S., Vieira, D., Lopes, N., Lam, E. W., Lunet, N., Schmitt, F. (2009). Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours. Breast Cancer Res., 11 (3), R40. DOI: 10.1186/bcr2327. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716509/.
]Search in Google Scholar
[
Asano, Y., Kashiwagi, S., Goto, W., Tanaka, S., Morisaki, T., Takashima, T., Noda, S., Onoda, N., Ohsawa, M., Hirakawa, K., Ohira, M. (2017). Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers, 9 (1), 4. DOI: 10.3390/cancers9010004. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295775/.
]Search in Google Scholar
[
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., Gianni, L. (2016). Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol., 13 (11), 674–690. https://doi.org/10.1038/nrclinonc.2016.66.10.1038/nrclinonc.2016.66546112227184417
]Search in Google Scholar
[
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., Mills, G. B., Lau, C. C., Brown, P. H. (2015). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res., 21 (7), 1688–1698. DOI: 10.1158/1078-0432.CCR-14-0432. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362882/.
]Search in Google Scholar
[
Chin, C. H., Chen, S. H., Wu, H. H., Ho, C. W., Ko, M. T., Lin, C. Y. (2014). cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol., 8 (Suppl 4), S11. https://doi.org/10.1186/1752-0509-8-S4-S11.10.1186/1752-0509-8-S4-S11429068725521941
]Search in Google Scholar
[
Chen, J., Bardes, E., Aronow, B., Jegga, A. (2009). ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucl. Acids Res., 37, W305-11. DOI: 10.1093/nar/gkp427. https://www.researchgate.net/publication/26236961_ToppGene_Suite_for_gene_list_enrichment_analysis_and_candidate_gene_prioritization.
]Search in Google Scholar
[
Cimino-Mathews, A., Subhawong, A. P., Elwood, H., Warzecha, H. N., Sharma, R., Park, B. H., Taube, J. M., Illei, P. B., Argani, P. (2013). Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum. Pathol., 44 (6), 959–965. DOI: 10.1016/j.humpath.2012.09.005. https://pubmed.ncbi.nlm.nih.gov/23260325/.10.1016/j.humpath.2012.09.005397817823260325
]Search in Google Scholar
[
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., Tamimi, R. M. (2011). Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses’ Health Study. Mod. Pathol., 24 (7), 924–931. https://www.nature.com/articles/modpathol201154#ethics.
]Search in Google Scholar
[
Dai, X., Cheng, H., Chen, X., Li, T., Zhang, J., Jin, G., Cai, D., Huang, Z. (2019). FOXA1 is prognostic of triple negative breast cancers by transcriptionally suppressing SOD2 and IL6. Int. J. Biol. Sci., 15 (5), 1030–1041. DOI: 10.7150/ijbs.31009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535797/.
]Search in Google Scholar
[
Dong, P., Yu, B., Pan, L., Tian, X., Liu, F. (2018). Identification of key genes and pathways in triple-negative breast cancer by integrated bioinformatics analysis. BioMed Res. Int., 2018, 2760918. DOI: org/10.1155/2018/2760918. https://www.hindawi.com/journals/bmri/2018/2760918/.
]Search in Google Scholar
[
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer, 144 (8), 1941–1953. https://doi.org/10.1002/ijc.31937.10.1002/ijc.3193730350310
]Search in Google Scholar
[
Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., Del Mastro, L., De Laurentiis, M., Puglisi, F., Arpino, G. (2018). Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat. Rev., 68, 102–110. https://doi.org/10.1016/j.ctrv.2018.06.005.10.1016/j.ctrv.2018.06.00529940524
]Search in Google Scholar
[
Gucalp, A., Traina, T. A. (2010). Triple-negative breast cancer: Role of the androgen receptor. Cancer J. (Sudbury, Mass.), 16 (1), 62–65. DOI: 10.1097/PPO.0b013e3181ce4ae1. https://pubmed.ncbi.nlm.nih.gov/20164692/.20164692
]Open DOISearch in Google Scholar
[
Guiu, S., Mollevi, C., Charon-Barra, C., Boissičre, F., Crapez, E., Chartron, E., Lamy, P. J., Gutowski, M., Bourgier, C., Romieu, G., Simony-Lafontaine, J., Jacot, W. (2018). Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Brit. J. Cancer, 119 (1), 76–79. DOI: 10.3390/cancers13040765. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918092/.791809233673133
]Open DOISearch in Google Scholar
[
Gupta, P. B., Kuperwasser, C. (2006). Contributions of estrogen to ER-negative breast tumor growth. J. Steroid Biochem. Mol. Biol., 102 (1–5), 71–78. DOI: 10.1016/j.jsbmb.2006.09.025. PMID: 17049443. https://www.sciencedirect.com/science/article/pii/S0960076006002706?via%3Dihub.17049443
]Open DOISearch in Google Scholar
[
Hwang, K. T., Kim, J., Jung, J., Chang, J. H., Chai, Y. J., Oh, S. W., Oh, S., Kim, Y. A., Park, S. B., Hwang, K. R. (2019). Impact of breast cancer sub-types on prognosis of women with operable invasive breast cancer: A population-based study using SEER Database. Clin. Cancer Res., 25 (6), 1970–1979. https://doi.org/10.1158/1078-0432.CCR-18-2782.10.1158/1078-0432.CCR-18-278230559169
]Search in Google Scholar
[
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., Toppmeyer, D. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol., 24 (36), 5652–5657. DOI: 10.1200/JCO.2006.06.5664. https://ascopubs.org/doi/10.1200/JCO.2006.06.5664?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.17116942
]Open DOISearch in Google Scholar
[
Ishibashi, Y., Ohtsu, H., Ikemura, M., Kikuchi, Y., Niwa, T., Nishioka, K., Uchida, Y., Miura, H., Aikou, S., Gunji, T., et al. (2017). Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci. Rep., 7 (1), 4846. DOI: 10.1038/s41598-017-05129-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501858/.550185828687783
]Open DOISearch in Google Scholar
[
Jamidi, S. K., Hu, J., Aphivatanasiri, C., Tsang, J. Y., Poon, I. K., Li, J. J., Chan, S. K., Cheung, S. Y., Tse, G. M. (2020). Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Histopathology, 77 (6), 936–948. https://doi.org/10.1111/his.14118.10.1111/his.1411832304249
]Search in Google Scholar
[
Kesson, E. M., Allardice, G. M., George, W. D., Burns, H. J., Morrison, D. S. (2012). Effects of multidisciplinary team working on breast cancer survival: Retrospective, comparative, interventional cohort study of 13 722 women. Brit. Med. J. (Clin. Res. ed.), 344, e2718. https://doi.org/10.1136/bmj.e2718.10.1136/bmj.e2718333987522539013
]Search in Google Scholar
[
Kim, S., Moon, B. I., Lim, W., Park, S., Cho, M. S., Sung, S. H. (2016). Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. Hum. Pathol., 55, 190–195. https://doi.org/10.1016/j.humpath.2016.04.013. https://www.sciencedirect.com/science/article/abs/pii/S0046817716300624?via%3Dihub.
]Search in Google Scholar
[
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig., 121 (7), 2750–2767. DOI: 10.1172/JCI45014. https://www.jci.org/articles/view/45014.312743521633166
]Open DOISearch in Google Scholar
[
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., Pietenpol, J. A. (2016). Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PloS One, 11 (6), e0157368. DOI: 10.1371/journal.pone.0157368. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911051/.491105127310713
]Open DOISearch in Google Scholar
[
Li, L., Huang, H., Zhu, M., Wu, J. (2021). Identification of hub genes and pathways of triple negative breast cancer by expression profiles analysis. Cancer Manag. Res., 13, 2095–2104. DOI: 10.2147/CMAR.S295951. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935333/.793533333688252
]Open DOISearch in Google Scholar
[
Liu, Z., Chen, S. (2010). ER regulates an evolutionarily conserved apoptosis pathway. Biochem. Biophys. Res. Comm., 400 (1), 34–38. DOI: 10.1016/j.bbrc.2010.07.132. https://www.sciencedirect.com/science/article/abs/pii/S0006291X10014658?via%3Dihub.20691160
]Open DOISearch in Google Scholar
[
Madsen, J., Nielsen, O., Torn¸e, I., Thim, L., Holmskov, U. (2007). Tissue localization of human trefoil factors 1, 2, and 3. J. Histochem. Cytochem., 55 (5), 505–513. DOI: 10.1369/jhc.6A7100.2007. https://journals.sagepub.com/doi/10.1369/jhc.6A7100.2007?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.17242463
]Open DOISearch in Google Scholar
[
Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., Osborne, C. K., De Placido, S., Arpino, G. (2012). Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res. Treat., 136 (3), 795–804. DOI: 10.1007/s10549-012-2315-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513514/.351351423124476
]Open DOISearch in Google Scholar
[
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., Symmans, W. F., Ueno, N. T. (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res., 19 (19), 5533–5540. DOI: 10.1158/1078-0432.CCR-13-0799. https://clincancerres.aacrjournals.org/content/19/19/5533.381359723948975
]Open DOISearch in Google Scholar
[
Mehra, R., Varambally, S., Ding, L., Shen, R., Sabel, M. S., Ghosh, D., Chinnaiyan, A. M., Kleer, C. G. (2005). Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res., 65 (24), 11259–11264. DOI: 10.1158/0008-5472.CAN-05-2495. https://cancerres.aacrjournals.org/content/65/24/11259.long.16357129
]Open DOISearch in Google Scholar
[
Mrklić, I., Pogorelić, Z., Capkun, V., Tomić, S. (2013). Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem., 115 (4), 344–348. DOI: 10.1016/j.acthis.2012.09.006. https://www.sciencedirect.com/science/article/abs/pii/S0065128112001158?via%3Dihub.23031358
]Open DOISearch in Google Scholar
[
Nallanthighal, S., Heiserman, J. P., Cheon, D. J. (2019). The role of the extracellular matrix in cancer stemness. Frontiers Cell Devel. Biol., 7, 86. https://doi.org/10.3389/fcell.2019.00086.10.3389/fcell.2019.00086662440931334229
]Search in Google Scholar
[
Reis-Filho, J. S., Pusztai, L. (2011). Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet, 378, 1812–1823. DOI: 10.1016/S0140-6736(11)61539-0. https://pubmed.ncbi.nlm.nih.gov/22098854/.22098854
]Open DOISearch in Google Scholar
[
Sartorius, C. A., Hanna, C. T., Gril, B., Cruz, H., Serkova, N. J., Huber, K. M., Kabos, P., Schedin, T. B., Borges, V. F., Steeg, P. S., Cittelly, D. M. (2016). Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene, 35 (22), 2881–2892. DOI: 10.1038/onc.2015.353. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809801/.480980126411365
]Open DOISearch in Google Scholar
[
Shaoxian, T., Baohua, Y., Xiaoli, X., Yufan, C., Xiaoyu, T., Hongfen, L., Rui, B., Xiangjie, S., Ruohong, S., Wentao, Y. (2017). Characterisation of GATA3 expression in invasive breast cancer: Differences in histological subtypes and immunohistochemically defined molecular subtypes. J. Clin. Pathol., 70 (11), 926–934. https://jcp.bmj.com/content/70/11/926.long.10.1136/jclinpath-2016-20413728428285
]Search in Google Scholar
[
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 98 (19), 10869–10874. DOI: 10.1073/pnas.191367098. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC58566/.5856611553815
]Open DOISearch in Google Scholar
[
Yi, J., Ren, L., Li, D., Wu, J., Li, W., Du, G., Wang, J. (2020). Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers. Biomed. Pharmacother., 124, 109827. DOI: 10.1016/j.biopha.2020.109827. https://www.sciencedirect.com/science/article/pii/S0753332220300172.31986408
]Open DOISearch in Google Scholar